Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 20, 2012, Pages 7765-7769

  Lee, Heehyoung ^a   Zhang, Peng ^b   Herrmann, Andreas ^a   Yang, Chunmei ^a   Xin, Hong ^a   Wang, Zhenghe ^b   Hoon, Dave S B ^c   Forman, Stephen J ^a   Jove, Richard ^a   Riggs, Arthur D ^a   Yu, Hua ^a,d  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHN WAYNE CANCER INSTITUTE   (United States)

^d Center for Translational Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; DNA METHYLTRANSFERASE 1; ESTROGEN RECEPTOR ALPHA; LYSINE; RESVERATROL; STAT3 PROTEIN;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER THERAPY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; GENE ACTIVATION; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INTERACTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL CULTURE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ACETYLATION; ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DNA METHYLATION; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOPRECIPITATION; MICE; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT3 TRANSCRIPTION FACTOR; STILBENES;

EID: 84861215508     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1205132109     Document Type: Article

References (43)

1. Yuan ZL, Guan YJ, Chatterjee D, Chin YE (2005) Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307:269-273. (Pubitemid 40116244)
2. Wang R, Cherukuri P, Luo J (2005) Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J Biol Chem 280:11528-11534. (Pubitemid 40418464)
3. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 9:798-809.
4. Yu H, Jove R (2004) The STATs of cancer-New molecular targets come of age. Nat Rev Cancer 4:97-105. (Pubitemid 38198738)
5. Zhang Q, et al. (2011) IL-2R common gamma-chain is epigenetically silenced by nucleophosphin- anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK. Proc Natl Acad Sci USA 108:11977-11982.
6. Zhang Q, Wang HY, Liu X, Wasik MA (2007) STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression. Nat Med 13:1341-1348. (Pubitemid 350073594)
7. Zhang Q, et al. (2005) STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc Natl Acad Sci USA 102:6948-6953. (Pubitemid 40675422)
8. Lee H, et al. (2011) A requirement of STAT3 DNA binding precludes Th-1 immunostimulatory gene expression by NF-κB in tumors. Cancer Res 71:3772-3780.
9. Niu G, et al. (2005) Role of Stat3 in regulating p53 expression and function. Mol Cell Biol 25:7432-7440. (Pubitemid 41170107)
10. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428. (Pubitemid 34587077)
11. Chen ZX, Riggs AD (2011) DNA methylation and demethylation in mammals. J Biol Chem 286:18347-18353.
12. Okano M, Bell DW, Haber DA, Li E (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99: 247-257. (Pubitemid 29519904)
13. Robert MF, et al. (2003) DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 33:61-65.
14. Rhee I, et al. (2002) DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416:552-556. (Pubitemid 34288859)
15. Johnston SR, et al. (1995) Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 55:3331-3338.
16. Mori T, et al. (2006) Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res 66:6692-6698. (Pubitemid 44085626)
17. Issa JP, Baylin SB, Belinsky SA (1996) Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure. Cancer Res 56: 3655-3658. (Pubitemid 26272007)
18. Issa JP, et al. (1994) Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 7:536-540.
19. Lapidus RG, et al. (1998) Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res 58:2515-2519. (Pubitemid 28275417)
20. Brinkman JA, El-Ashry D (2009) ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers. J Mammary Gland Biol Neoplasia 14:67-78.
21. Ying J, et al. (2009) DLEC1 is a functional 3p22.3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers. Br J Cancer 100:663-669.
22. Shively JE (2004) CEACAM1 and hyperplastic polyps: New links in the chain of events leading to colon cancer. Oncogene 23:9303-9305.
23. Ren C, et al. (2002) mRTVP-1, a novel p53 target gene with proapoptotic activities. Mol Cell Biol 22:3345-3357. (Pubitemid 34453976)
24. Zaki MH, Vogel P, Body-Malapel M, Lamkanfi M, Kanneganti TD (2010) IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J Immunol 185:4912-4920.
25. Herman JG, et al. (1995) Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525-4530.
26. Xi S, et al. (2006) Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis. J Natl Cancer Inst 98:181-189. (Pubitemid 43205480)
27. Howitz KT, et al. (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425:191-196. (Pubitemid 37150899)
28. Nie Y, et al. (2009) STAT3 inhibition of gluconeogenesis is downregulated by SirT1. Nat Cell Biol 11:492-500.
29. Cocconi G, et al. (1992) Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 327:516-523.
30. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51. (Pubitemid 43054973)
31. Gregory PD, Wagner K, Hörz W (2001) Histone acetylation and chromatin remodeling. Exp Cell Res 265:195-202. (Pubitemid 32980207)
32. Zhang J, Yang PL, Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9:28-39.
33. Hunter T (2009) Tyrosine phosphorylation: Thirty years and counting. Curr Opin Cell Biol 21:140-146.
34. Kotha A, et al. (2006) Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther 5: 621-629.
35. Chen Lf, Fischle W, Verdin E, Greene WC (2001) Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293:1653-1657.
36. Lee H, et al. (2009) Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 15:283-293.
37. Egger G, Liang G, Aparicio A, Jones PA (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457-463. (Pubitemid 38715140)
38. Yang X, Lay F, Han H, Jones PA (2010) Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci 31:536-546.
39. Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: Past, present and future. Nat Rev Drug Discov 5:37-50.
40. Zhang X, et al. (2008) Epitope tagging of endogenous proteins for genome-wide ChIP-chip studies. Nat Methods 5:163-165. (Pubitemid 351181743)
41. Lee H, et al. (2010) STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med 16:1421-1428.
42. de Maat MF, et al. (2007) Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. J Clin Oncol 25:4887-4894.
43. Mohn F, Weber M, Schübeler D, Roloff TC (2009) Methylated DNA immunoprecipitation (MeDIP). Methods Mol Biol 507:55-64.